Small-molecule activation of the TRAIL receptor DR5 in human cancer cells

Gelin Wang, Xiaoming Wang, Hong Yu, Shuguang Wei, Noelle Williams, Daniel L. Holmes, Randal Halfmann, Jacinth Naidoo, Lai Wang, Lin Li, She Chen, Patrick Harran, Xiaoguang Lei, Xiaodong Wang

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) activates apoptosis through the death receptors DR4 and DR5. Because of its superior safety profile and high tumor specificity compared to other TNF family members, recombinant soluble TRAIL and agonistic antibodies against its receptors are actively being developed for clinical cancer therapy. Here, we describe the identification and characterization of the small molecules that directly target DR5 to initiate apoptosis in human cancer cells. The activity was initially discovered through a high-throughput chemical screen for compounds that promote cell death in synergy with a small-molecule mimetic of Smac, the antagonist for inhibitor of apoptosis protein. Structure-activity relationship studies yielded a more potent analog called bioymifi, which can act as a single agent to induce DR5 clustering and aggregation, leading to apoptosis. Thus, this study identified potential lead compounds for the development of small-molecule TRAIL mimics targeting DR5 for cancer therapy.

Original languageEnglish (US)
Pages (from-to)84-89
Number of pages6
JournalNature Chemical Biology
Volume9
Issue number2
DOIs
StatePublished - Feb 2013

Fingerprint

TNF-Related Apoptosis-Inducing Ligand Receptors
TNF-Related Apoptosis-Inducing Ligand
Apoptosis
Neoplasms
Tumor Necrosis Factor-alpha
Inhibitor of Apoptosis Proteins
Death Domain Receptors
Structure-Activity Relationship
Cluster Analysis
Cell Death
Ligands
Safety
Antibodies
Therapeutics

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Biology

Cite this

Small-molecule activation of the TRAIL receptor DR5 in human cancer cells. / Wang, Gelin; Wang, Xiaoming; Yu, Hong; Wei, Shuguang; Williams, Noelle; Holmes, Daniel L.; Halfmann, Randal; Naidoo, Jacinth; Wang, Lai; Li, Lin; Chen, She; Harran, Patrick; Lei, Xiaoguang; Wang, Xiaodong.

In: Nature Chemical Biology, Vol. 9, No. 2, 02.2013, p. 84-89.

Research output: Contribution to journalArticle

Wang, G, Wang, X, Yu, H, Wei, S, Williams, N, Holmes, DL, Halfmann, R, Naidoo, J, Wang, L, Li, L, Chen, S, Harran, P, Lei, X & Wang, X 2013, 'Small-molecule activation of the TRAIL receptor DR5 in human cancer cells', Nature Chemical Biology, vol. 9, no. 2, pp. 84-89. https://doi.org/10.1038/nchembio.1153
Wang, Gelin ; Wang, Xiaoming ; Yu, Hong ; Wei, Shuguang ; Williams, Noelle ; Holmes, Daniel L. ; Halfmann, Randal ; Naidoo, Jacinth ; Wang, Lai ; Li, Lin ; Chen, She ; Harran, Patrick ; Lei, Xiaoguang ; Wang, Xiaodong. / Small-molecule activation of the TRAIL receptor DR5 in human cancer cells. In: Nature Chemical Biology. 2013 ; Vol. 9, No. 2. pp. 84-89.
@article{335d0721c9724f40b61186bf4f971ea2,
title = "Small-molecule activation of the TRAIL receptor DR5 in human cancer cells",
abstract = "Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) activates apoptosis through the death receptors DR4 and DR5. Because of its superior safety profile and high tumor specificity compared to other TNF family members, recombinant soluble TRAIL and agonistic antibodies against its receptors are actively being developed for clinical cancer therapy. Here, we describe the identification and characterization of the small molecules that directly target DR5 to initiate apoptosis in human cancer cells. The activity was initially discovered through a high-throughput chemical screen for compounds that promote cell death in synergy with a small-molecule mimetic of Smac, the antagonist for inhibitor of apoptosis protein. Structure-activity relationship studies yielded a more potent analog called bioymifi, which can act as a single agent to induce DR5 clustering and aggregation, leading to apoptosis. Thus, this study identified potential lead compounds for the development of small-molecule TRAIL mimics targeting DR5 for cancer therapy.",
author = "Gelin Wang and Xiaoming Wang and Hong Yu and Shuguang Wei and Noelle Williams and Holmes, {Daniel L.} and Randal Halfmann and Jacinth Naidoo and Lai Wang and Lin Li and She Chen and Patrick Harran and Xiaoguang Lei and Xiaodong Wang",
year = "2013",
month = "2",
doi = "10.1038/nchembio.1153",
language = "English (US)",
volume = "9",
pages = "84--89",
journal = "Nature Chemical Biology",
issn = "1552-4450",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Small-molecule activation of the TRAIL receptor DR5 in human cancer cells

AU - Wang, Gelin

AU - Wang, Xiaoming

AU - Yu, Hong

AU - Wei, Shuguang

AU - Williams, Noelle

AU - Holmes, Daniel L.

AU - Halfmann, Randal

AU - Naidoo, Jacinth

AU - Wang, Lai

AU - Li, Lin

AU - Chen, She

AU - Harran, Patrick

AU - Lei, Xiaoguang

AU - Wang, Xiaodong

PY - 2013/2

Y1 - 2013/2

N2 - Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) activates apoptosis through the death receptors DR4 and DR5. Because of its superior safety profile and high tumor specificity compared to other TNF family members, recombinant soluble TRAIL and agonistic antibodies against its receptors are actively being developed for clinical cancer therapy. Here, we describe the identification and characterization of the small molecules that directly target DR5 to initiate apoptosis in human cancer cells. The activity was initially discovered through a high-throughput chemical screen for compounds that promote cell death in synergy with a small-molecule mimetic of Smac, the antagonist for inhibitor of apoptosis protein. Structure-activity relationship studies yielded a more potent analog called bioymifi, which can act as a single agent to induce DR5 clustering and aggregation, leading to apoptosis. Thus, this study identified potential lead compounds for the development of small-molecule TRAIL mimics targeting DR5 for cancer therapy.

AB - Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) activates apoptosis through the death receptors DR4 and DR5. Because of its superior safety profile and high tumor specificity compared to other TNF family members, recombinant soluble TRAIL and agonistic antibodies against its receptors are actively being developed for clinical cancer therapy. Here, we describe the identification and characterization of the small molecules that directly target DR5 to initiate apoptosis in human cancer cells. The activity was initially discovered through a high-throughput chemical screen for compounds that promote cell death in synergy with a small-molecule mimetic of Smac, the antagonist for inhibitor of apoptosis protein. Structure-activity relationship studies yielded a more potent analog called bioymifi, which can act as a single agent to induce DR5 clustering and aggregation, leading to apoptosis. Thus, this study identified potential lead compounds for the development of small-molecule TRAIL mimics targeting DR5 for cancer therapy.

UR - http://www.scopus.com/inward/record.url?scp=84872677190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872677190&partnerID=8YFLogxK

U2 - 10.1038/nchembio.1153

DO - 10.1038/nchembio.1153

M3 - Article

C2 - 23292651

AN - SCOPUS:84872677190

VL - 9

SP - 84

EP - 89

JO - Nature Chemical Biology

JF - Nature Chemical Biology

SN - 1552-4450

IS - 2

ER -